

**ABSTRACT OF THE DISCLOSURE**

New peptide compounds are capable of binding to fibroblast growth factor receptor (FGFR), said compounds comprising two individual amino acid sequences derived from NCAM, being identical or different, said two amino acid sequences being connected to each other through a specific linker, wherein at least one of the two amino acid sequences is capable of binding to FGFR. These compounds are obtainable by the ligand presenting assembly (LPA) method. The compounds and pharmaceutical compositions comprising them may be used for the treatment or prevention of different pathological conditions, wherein FGFR plays a role in pathology and/or recovery from the disease.